C5 and Alzheimer disease: In Mild Cognitive Impairment (MCI) that progresses to AD dementia within three years and in early clinically evident AD, exosome marker CD81-normalized ADE levels of complement effector components of the classical and alternative pathways including C3b and C5b-9 were higher than in matched cognitively normal controls11,13.